Skip to main
ICLR

ICON (ICLR) Stock Forecast & Price Target

ICON (ICLR) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 21%
Buy 29%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Icon has demonstrated a positive trend with a gross business awards increase of 11% on a sequential basis, driven by successful partnerships with biotech and pharmaceutical clients. The company has successfully met or exceeded its financial targets following the PRA acquisition, positioning itself advantageously amid potential funding uncertainties in the market. Additionally, Icon's favorable client mix contributes to an improving win rate, enhancing its capacity to capitalize on the growing clinical trial research sector within the contract research organization market.

Bears say

Icon's stock outlook is negatively impacted by lowered EBITDA margin expectations, which have decreased to the high-19% range, compared to previous anticipations of around 20% for both the current year and 2025. Contributing factors to this outlook include uncertainties surrounding slowed clinical trial activity due to pharmaceutical companies reprioritizing their projects and broader biotech funding challenges. Additionally, potential risks such as inflationary pressures and a slowdown in Pharma R&D spending further complicate the company's revenue synergy projections from the PRA transaction.

ICON (ICLR) has been analyzed by 14 analysts, with a consensus rating of Buy. 21% of analysts recommend a Strong Buy, 29% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ICON (ICLR) Forecast

Analysts have given ICON (ICLR) a Buy based on their latest research and market trends.

According to 14 analysts, ICON (ICLR) has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $206.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $206.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ICON (ICLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.